| |
Group
|
Descriptive statistics Mean (SD)
|
Change at 15 months: Within-group p-value
|
Change at 15 months: Between groups
|
|---|
| | |
Workshop
|
Final
|
Adjusted mean (SE)
|
95% CI
|
Between-group p-value
|
|---|
|
HbA1c*,%
|
I (n = 73)
|
7.12 (0.42)
|
7.09 (0.41)
|
0.34
|
0.02 (0.04)
|
(−0.05 to 0.09)
|
0.63
|
|
C (n = 76)
|
7.20 (0.52)
|
7.15 (0.51)
|
0.13
| | | |
|
% patients HbA1c ≤ 7.0%
|
I (n = 73)
|
58.40 (16.20)
|
58.68 (15.40)
|
0.76
|
−1.22 (1.30)
|
(−3.78 to 1.35)
|
0.35
|
|
C (n = 76)
|
55.95 (15.65)
|
57.58 (16.12)
|
0.15
| | | |
|
FPG† level in mmol/L
|
I (n = 71)
|
7.86 (0.67)
|
7.78 (0.68)
|
0.13
|
0.01 (0.07)
|
(−0.13 to 0.15)
|
0.85
|
|
C (n = 70)
|
7.89 (0.69)
|
7.82 (0.68)
|
0.22
| | | |
|
% patients prescribed OAD‡
|
I (n = 73)
|
80.87 (10.83)
|
83.32 (9.98)
|
< 0.001
|
0.87 (0.65)
|
(−0.42 to 2.16)
|
0.18
|
|
C (n = 76)
|
79.24 (12.06)
|
81.12 (11.14)
|
< 0.001
| | | |
|
OAD score§
|
I (n = 73)
|
1.32 (0.20)
|
1.37 (0.21)
|
< 0.001
|
0.01 (0.02)
|
(−0.03 to 0.04)
|
0.65
|
|
C (n = 76)
|
1.38 (0.21)
|
1.41 (0.24)
|
0.02
| | | |
|
% patients prescribed insulin
|
I (n = 73)
|
11.53 (8.93)
|
17.14 (10.64)
|
< 0.001
|
−1.06 (0.88)
|
(−2.80 to 0.69)
|
0.23
|
|
C (n = 76)
|
11.53 (8.51)
|
18.38 (10.82)
|
< 0.001
| | | |
|
Insulin daily dose (units)
|
I (n = 61)
|
47.91 (21.24)
|
53.64 (22.71)
|
< 0.01
|
5.96 (2.83)
|
(0.35 to 11.56)
|
0.04
|
|
C (n = 57)
|
57.19 (26.21)
|
54.94 (23.65)
|
0.30
| | | |
|
Intensification of diabetes management**
|
I (n = 73)
|
--
|
31.59 (14.17)
|
--
|
−0.29 (2.35)
|
(−4.93 to 4.34)
|
0.90
|
|
C (n = 76)
|
--
|
32.80 (14.91)
|
--
| | | |
- Note: CI = confidence interval, ANCOVA = analysis of covariance with treatment, stratum, and pooled site effects and the corresponding baseline value as covariate used for the change from baseline (difference: endpoint-baseline) with p-values based on actual data.
-
*HbA1c – glycosylated hemoglobin.
-
†FPG – fasting plasma glucose.
-
‡OAD – oral anti-diabetes drug.
-
§OAD score = sum of all OADs prescribed; OAD ½ to maximum dose = 1 OAD.
-
¶These are between-group results where change from workshop to 15 months was compared between intervention and control groups using ANCOVA, treatment effect is adjusted for baseline effect and pooled site effect.
-
**Intensification of diabetes management – Increased dose of OAD or insulin, increased OAD score, or the addition of insulin; Intensification is a one-time post workshop variable, therefore no within group differences.
